Skip to content
  • Our Care
    • Product
    • Scientific Research
    • FAQs
  • About
    • Press Room
    • About Us
    • Meet the Team
    • Contact Us
  • Prescriber Information
Start Your Treatment
  • Product
  • Scientific Research
  • FAQs
  • Press Room
  • About Us
  • Meet the Team
  • Contact Us
  • Prescriber Information
BlogVon Greer2023-09-29T18:50:13+00:00
  • how long does menopause last

    June 27, 2023

    How Long Does Menopause Last & What to Expect

    Read More
  • menopause and bladder control

    June 20, 2023

    Can Menopause Affect Bladder Control?

    Read More
  • how menopause impacts cholesterol

    June 14, 2023

    The Impact Menopause Has on Cholesterol

    Read More
  • weight and menopause

    June 8, 2023

    Navigating Weight Loss After 40: Overcoming Challenges from Menopause

    Read More
  • thyroid conditions and menopause

    May 31, 2023

    Are Thyroid Conditions Connected to Menopause?

    Read More
  • hair loss_perimenopause_menopause_pearlpak_estriol

    May 23, 2023

    Hair Loss in Women: Causes, Prevention, and Solutions

    Read More
  • May 17, 2023

    The 7 Causes of Night Sweats

    Read More
  • woman with diabetes and menopause

    May 9, 2023

    Diabetes and Menopause: How They’re Connected

    Read More
  • perimenopause and the menstrual cycle

    May 5, 2023

    How Perimenopause Affects Your Menstrual Cycle

    Read More
  • hot flash triggers during menopause

    April 25, 2023

    Avoiding Hot Flash Triggers and How to Keep them Tame

    Read More
Previous345Next

© Copyright 2025 CleopatraRX™. All Rights Reserved. View our Privacy Policy. and Terms and Conditions.

*PearlPAK™️ dose system is not intended to treat neurological diseases including dementia and Alzheimer’s Disease. It is specifically designed to target cognitive difficulties in perimenopause and early menopausal women only. If you are concerned about neurological disease or have a family history of neurological disease, contact your physician.

CleopatraRX™ and PearlPAK™ are trademarks of CleopatraRX Development, LLC. CleopatraRX™ is a service mark and is used throughout this website to represent the services offered by CleopatraRX Development, LLC. PearlPAK™ is a dosage product for use as a drug/routine system and/or treatment.

The PearlPAK™️ drug/routine system is protected by U.S. Patent No. 10,369,158 – PHARMACEUTICAL PACKAGING FOR ESTRIOL THERAPY – which relates to novel packaged pharmaceutical products for the treatment of neurodegenerative diseases, such as multiple sclerosis, and methods of using these products.

Estriol Therapy U.S. Patent No. 9,962,395 – COMPOSITIONS AND METHODS FOR MAINTAINING COGNITIVE FUNCTION – Provides methods for reducing the progression of cognitive decline in a post-menopausal woman using a continuous regimen of estrogen in combination with periodic administration of a progestogen.

*PearlPAK™ dose system is not intended to treat neurological diseases including dementia and Alzheimer’s Disease. It is specifically designed to target cognitive difficulties in perimenopause and early menopausal women only. If you are concerned about neurological disease or have a family history of neurological disease, contact your physician.

CleopatraRX™ and PearlPAK™ are trademarks of CleopatraRX Development, LLC. CleopatraRX™ is a service mark and used throughout this website to represent the services offered by CleopatraRX Development, LLC. PearlPAK™ is a dosage product is for use as a drug/routine system and/or treatment.

The PearlPAK™ drug/routine system is protected by U.S. Patent No. 10,369,158 – PHARMACEUTICAL PACKAGING FOR ESTRIOL THERAPY – which relates to novel packaged pharmaceutical products for the treatment of neurodegenerative diseases, such as multiple sclerosis, and methods of using these products.

Estriol Therapy U.S. Patent No. 9,962,395 – COMPOSITIONS AND METHODS FOR MAINTAINING COGNITIVE FUNCTION – Provides methods for reducing the progression of cognitive decline in a post – menopausal woman using a continuous regimen of estrogen in combination with periodic administration of a progestogen.

Page load link
Go to Top